- Home
- GAB vs ATAI Comparison
GAB vs ATAI Comparison
Compare GAB & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAB
- ATAI
- Stock Information
- Founded
- GAB 1986
- ATAI 2018
- Country
- GAB United States
- ATAI Netherlands
- Employees
- GAB N/A
- ATAI N/A
- Industry
- GAB Investment Managers
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- GAB Finance
- ATAI Health Care
- Exchange
- GAB Nasdaq
- ATAI Nasdaq
- Market Cap
- GAB 1.9B
- ATAI 1.6B
- IPO Year
- GAB N/A
- ATAI 2021
- Fundamental
- Price
- GAB $6.16
- ATAI $3.78
- Analyst Decision
- GAB
- ATAI Strong Buy
- Analyst Count
- GAB 0
- ATAI 5
- Target Price
- GAB N/A
- ATAI $14.00
- AVG Volume (30 Days)
- GAB 667.8K
- ATAI 5.0M
- Earning Date
- GAB 01-01-0001
- ATAI 11-12-2025
- Dividend Yield
- GAB 10.91%
- ATAI N/A
- EPS Growth
- GAB N/A
- ATAI N/A
- EPS
- GAB N/A
- ATAI N/A
- Revenue
- GAB N/A
- ATAI $3,018,000.00
- Revenue This Year
- GAB N/A
- ATAI $736.04
- Revenue Next Year
- GAB N/A
- ATAI N/A
- P/E Ratio
- GAB N/A
- ATAI N/A
- Revenue Growth
- GAB N/A
- ATAI 811.78
- 52 Week Low
- GAB $4.56
- ATAI $1.15
- 52 Week High
- GAB $5.88
- ATAI $6.75
- Technical
- Relative Strength Index (RSI)
- GAB 60.04
- ATAI 32.71
- Support Level
- GAB $5.90
- ATAI $3.60
- Resistance Level
- GAB $6.05
- ATAI $3.89
- Average True Range (ATR)
- GAB 0.08
- ATAI 0.26
- MACD
- GAB 0.02
- ATAI -0.04
- Stochastic Oscillator
- GAB 86.21
- ATAI 16.75
About GAB Gabelli Equity Trust Inc. (The)
Gabelli Equity Trust Inc is a non-diversified closed-end management investment company. Its primary investment objective is the long-term growth of capital with income as a secondary objective. The Fund invests at least its assets in equity securities under normal market conditions. Its equity portfolio includes common stock, preferred stock, convertible or exchangeable securities, and warrants and rights to purchase such securities selected by the Investment Adviser. The company invests in various sectors, of which Food & Beverage, Financial Services, Equipment and Supplies, Entertainment, Consumer Products, Health Care, Diversified Industrial, Business Services, Consumer Services and others.
About ATAI ATAI Life Sciences N.V.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.